Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial
暂无分享,去创建一个
K. Minden | E. Alexeeva | A. Reiff | E. Silverman | V. Chasnyk | A. Martini | M. Loza | A. van Royen‐Kerkhof | Keith Gilmer | Zhenhua Xu | H. Brunner | B. Lauwerys | D. Lovell | C. Abud-Mendoza | I. Foeldvari | V. Keltsev | N. Ruperto | N. Rubio-Pérez | F. Sztajnbok | L. Kim | G. Horneff | D. Kingsbury | E. Smolewska | J. Leu | I. Nikishina | N. Tzaribachev | V. Panavienė | R. Joos | S. Lamberth | M. Bandeira | W. Emminger | Maria del Rocio Maldonado Velázquez | K. Gilmer | A. van Royen-Kerkhof
[1] E. Alexeeva,et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. , 2015, Annals of the rheumatic diseases.
[2] D. Foell,et al. Management of juvenile idiopathic arthritis: hitting the target , 2015, Nature Reviews Rheumatology.
[3] C. Wouters,et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.
[4] A. Martini,et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. , 2012, Arthritis and rheumatism.
[5] Bin Huang,et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis , 2011, Arthritis care & research.
[6] Alberto Martini,et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features , 2011, Arthritis care & research.
[7] A. Martini,et al. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. , 2010, Arthritis and rheumatism.
[8] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of pharmacology & pharmacotherapeutics.
[9] Mahboob Rahman,et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial , 2009, The Lancet.
[10] Alberto Martini,et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. , 2009, Arthritis and rheumatism.
[11] Mahboob Rahman,et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study , 2008, Annals of the rheumatic diseases.
[12] K. Minden,et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. , 2008, The New England journal of medicine.
[13] A. Martini,et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2008, The Lancet.
[14] E. Giannini,et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. , 2004, The Journal of rheumatology.
[15] A. Martini,et al. International research networks in pediatric rheumatology: the PRINTO perspective , 2004, Current opinion in rheumatology.
[16] M. Suarez‐Almazor,et al. International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .
[17] E. Giannini,et al. Preliminary definition of disease flare in juvenile rheumatoid arthritis. , 2002, The Journal of rheumatology.
[18] S. Cavuto,et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. , 2001, Clinical and experimental rheumatology.
[19] A. Reiff,et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.
[20] D. Felson,et al. Preliminary definition of improvement in juvenile arthritis. , 1997, Arthritis and rheumatism.
[21] B. Frederick,et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. , 2012, Clinical therapeutics.
[22] B. Thiers. Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis , 2009 .
[23] D. Heijde,et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab , 2007, Annals of the rheumatic diseases.
[24] Recommendations guiding physicians in biomedical research involving human subjects. World Medical Association Declaration of Helsinki. , 1994, Le Journal medical libanais. The Lebanese medical journal.
[25] C. Werning. [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.